<DOC>
	<DOCNO>NCT00005969</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal tretinoin treat patient recurrent refractory Hodgkin 's disease .</brief_summary>
	<brief_title>Liposomal Tretinoin Treating Patients With Recurrent Refractory Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , failure free survival , progression free survival patient recurrent refractory Hodgkin 's disease treat tretinoin liposome . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord prior response treatment ( refractory v recurrent v post marrow transplant ) . Patients receive tretinoin liposome IV 30 minute every day 28 day . Treatment continue every 28 day total 6 course absence disease progression unacceptable toxicity . Patients eligible stem cell marrow transplant receive least 2 course cross transplant . Patients follow every 3 month . PROJECTED ACCRUAL : A total 105 patient ( 35 per stratum ) accrue study 2-3 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory Hodgkin 's disease Recurrent partial complete response initial therapy OR Refractory response progression initial therapy At least 2 prior treatment regimen ( radiotherapy consider separate part plan combined modality ) Bidimensionally measurable disease No active CNS disease PATIENT CHARACTERISTICS : Age : 12 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 500/mm3 Platelet count least 20,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGPT le 4 time upper limit normal Renal : Creatinine great 3.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception Must eligible willing undergo treatment high priority HIV negative No prior malignancy within last 5 year except basal cell carcinoma skin carcinoma situ cervix treat curative intent No concurrent serious illness active infection No mental social reason may preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior autologous stem cell marrow transplant No prior allogenic stem cell marrow transplant Chemotherapy : See Disease Characteristics Must recover last regimen No prior retinoids , include tretinoin Endocrine therapy : No concurrent steroids Radiotherapy : See Disease Characteristics Must recover last regimen Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>